Implementing food-based dietary guidelines for - United Nations ...

More documents

Recommendations

Info

S114 Taylor SL, Stengard JH, Salomaa V, Vartiainen E, Perola M, Boerwinkle E, Sing CF. Apolipoprotein E variation at the sequence haplotype level: Implications for the origin and maintenance of a major human polymorphism. Am J Hum Genet 2000;67:881–900. 84. Ordovas JM, Corella D. Nutritional genomics. Annu Rev Genomics Hum Genet 2004;5:71–118. 85. Ordovas JM. The quest for cardiovascular health in the genomic era: Nutrigenetics and plasma lipoproteins. Proc Nutr Soc 2004;63:145–52. 86. Edmonds DK, Lindsay KS, Miller JF, Williamson E, Wood PJ. Early embryonic mortality in women. Fertil Steril 1982;38:447–53. 87. Edwards RG. Recent scientific and medical advances in assisted human conception. Int J Dev Biol 1997;41: 255–62. 88. Nelen WL, Blom HJ, Steegers EA, den Heijer M, Eskes TK. Hyperhomocysteinemia and recurrent early pregnancy loss: A meta-analysis. Fertil Steril 2000;74: 1196–9. 89. Nelen WL, Blom HJ, Steegers EA, den Heijer M, Thomas CM, Eskes TK. Homocysteine and folate levels as risk factors for recurrent early pregnancy loss. Obstet Gynecol 2000;95:519–24. 90. Nelen WL, Blom HJ, Thomas CM, Steegers EA, Boers GH, Eskes TK. Methylenetetrahydrofolate reductase polymorphism affects the change in homocysteine and folate concentrations resulting from low dose folic acid supplementation in women with unexplained recurrent miscarriages. J Nutr 1998;128:1336–41. 91. Shelnutt KP, Kauwell GP, Gregory JF 3rd, Maneval DR, Quinlivan EP, Theriaque DW, Henderson GN, Bailey LB. Methylenetetrahydrofolate reductase 677C→T polymorphism affects DNA methylation in response to controlled folate intake in young women. J Nutr Biochem 2004;15:554–60. 92. Hunt JR, Zeng H. Iron absorption by heterozygous carriers of the HFE C282Y mutation associated with hemochromatosis. Am J Clin Nutr 2004;80:924–31. 93. Swanson CA. Iron intake and regulation: Implications for iron deficiency and iron overload. Alcohol 2003;30:99–102. 94. Moirand R, Guyader D, Mendler MH, Jouanolle AM, Le Gall JY, David V, Brissot P, Deugnier Y. HFE based re-evaluation of heterozygous hemochromatosis. Am J Med Genet 2002;111:356–61. 95. Baier LJ, Hanson RL. Genetic studies of the etiology of type 2 diabetes in Pima Indians: Hunting for pieces to a complicated puzzle. Diabetes 2004;53:1181–6. 96. Tseung CW, McMahon LG, Vazquez J, Pohl J, Gregory JF 3rd. Partial amino acid sequence and mRNA analysis of cytosolic pyridoxine-beta-D-glucoside hydrolase from porcine intestinal mucosa: Proposed derivation from the lactase-phlorizin hydrolase gene. Biochem J 2004; 380(pt 1):211–8. 97. Mackey AD, McMahon RJ, Townsend JH, Gregory JF 3rd. Uptake, hydrolysis, and metabolism of pyridoxine-5’-beta-D-glucoside in Caco-2 cells. J Nutr 2004;134:842–6. 98. Seifried HE, Anderson DE, Sorkin BC, Costello RB. Free radicals: The pros and cons of antioxidants. Executive summary report. J Nutr 2004;134:3143S–63S. 99. Zeisel SH. Antioxidants suppress apoptosis. J Nutr P. J. Stover 2004;134:3179S–80S. 100. Csete M, Doyle J. Bow ties, metabolism and disease. Trends Biotechnol 2004;22:446–50. 101. Pennisi E. Evolution of developmental diversity. Evodevo devotees eye ocular origins and more. Science 2002;296:1010–1. 102. Pasqualetti M, Neun R, Davenne M, Rijli FM. Retinoic acid rescues inner ear defects in Hoxa1 deficient mice. Nat Genet 2001;29:34–9. 103. Finnell RH, Spiegelstein O, Wlodarczyk B, Triplett A, Pogribny IP, Melnyk S, James JS. DNA methylation in Folbp1 knockout mice supplemented with folic acid during gestation. J Nutr 2002;132(8 suppl):2457S–61S. 104. Seckl JR, Meaney MJ. Glucocorticoid programming. Ann NY Acad Sci 2004;1032:63–84. 105. Seckl JR, Walker BR. Minireview: 11beta-hydroxysteroid dehydrogenase type 1—a tissue-specific amplifier of glucocorticoid action. Endocrinology 2001;142:1371–6. 106. McMillen IC, Robinson JS. Developmental origins of the metabolic syndrome: Prediction, plasticity, and programming. Physiol Rev 2005;85:571–633. 107. Seckl JR. Prenatal glucocorticoids and long-term programming. Eur J Endocrinol 2004;151(suppl 3):U49–62. 108. White PC, Mune T, Agarwal AK. 11 beta-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocr Rev 1997;18:135–56. 109. Bertram C, Trowern AR, Copin N, Jackson AA, Whorwood CB. The maternal diet during pregnancy programs altered expression of the glucocorticoid receptor and type 2 11beta-hydroxysteroid dehydrogenase: Potential molecular mechanisms underlying the programming of hypertension in utero. Endocrinology 2001;142:2841–53. 110. Drake AJ, Walker BR, Seckl JR. Intergenerational consequences of fetal programming by in utero exposure to glucocorticoids in rats. Am J Physiol Regul Integr Comp Physiol 2005;288:R34–8. 111. Gatford KL, Wintour EM, De Blasio MJ, Owens JA, Dodic M. Differential timing for programming of glucose homoeostasis, sensitivity to insulin and blood pressure by in utero exposure to dexamethasone in sheep. Clin Sci (Lond) 2000;98:553–60. 112. Valera A, Pujol A, Pelegrin M, Bosch F. Transgenic mice overexpressing phosphoenolpyruvate carboxykinase develop non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci USA 1994;91:9151–4. 113. Rosella G, Zajac JD, Kaczmarczyk SJ, Andrikopoulos S, Proietto J. Impaired suppression of gluconeogenesis induced by overexpression of a noninsulin-responsive phosphoenolpyruvate carboxykinase gene. Mol Endocrinol 1993;7:1456–62. 114. Asipu A, Hayward BE, O’Reilly J, Bonthron DT. Properties of normal and mutant recombinant human ketohexokinases and implications for the pathogenesis of essential fructosuria. Diabetes 2003;52:2426–32. 115. Cox TM. The genetic consequences of our sweet tooth. Nat Rev Genet 2002;3:481–7. 116. Aviv A, Hollenberg NK, Weder AB. Sodium glomerulopathy: Tubuloglomerular feedback and renal injury in African Americans. Kidney Int 2004;65:361–8. 117. Messier W, Stewart CB. Episodic adaptive evolution of primate lysozymes. Nature 1997;385:151–4. 118. Zhang J, Zhang YP, Rosenberg HF. Adaptive evolution
Human nutrition and genetic variation of a duplicated pancreatic ribonuclease gene in a leafeating monkey. Nat Genet 2002;30:411–5. 119. Wu W, Goodman M, Lomax MI, Grossman LI. Molecular evolution of cytochrome C oxidase subunit IV: Evidence for positive selection in simian primates. J Mol Evol 1997;44:477–91. 120. Wooding SP, Watkins WS, Bamshad MJ, Dunn DM, Weiss RB, Jorde LB. DNA sequence variation in a 3.7-kb noncoding sequence 5’ of the CYP1A2 gene: Implications for human population history and natural selection. Am J Hum Genet 2002;71:528–42. 121. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, Selhub J, Rozen R. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996;93:7–9. 122. Tsai MY, Yang F, Bignell M, Aras O, Hanson NQ. Relation between plasma homocysteine concentration, the 844ins68 variant of the cystathionine beta-synthase gene, and pyridoxal-5’-phosphate concentration. Mol Genet Metab 1999;67:352–6. 123. Afman LA, Trijbels FJ, Blom HJ. The H475Y polymorphism in the glutamate carboxypeptidase II gene increases plasma folate without affecting the risk for neural tube defects in humans. J Nutr 2003;133:75–7. 124. Devlin AM, Ling EH, Peerson JM, Fernando S, Clarke R, Smith AD, Halsted CH. Glutamate carboxypeptidase II: A polymorphism associated with lower levels of serum folate and hyperhomocysteinemia. Hum Mol Genet 2000;9:2837–44. 125. Uitterlinden AG, Fang Y, Bergink AP, van Meurs JB, van Leeuwen HP, Pols HA. The role of vitamin D receptor gene polymorphisms in bone biology. Mol Cell Endocrinol 2002;197:15–21. 126. Griffiths W, Cox T. Haemochromatosis: Novel gene discovery and the molecular pathophysiology of iron metabolism. Hum Mol Genet 2000;9:2377–82. 127. Zhao R, Russell RG, Wang Y, Liu L, Gao F, Kneitz B, Edelmann W, Goldman ID. Rescue of embryonic lethality in reduced folate carrier-deficient mice by maternal folic acid supplementation reveals early neonatal failure of hematopoietic organs. J Biol Chem 2001; S115 276:10224–8. 128. Geller DS. A genetic predisposition to hypertension? Hypertension 2004;44:27–8. 129. Jeck N, Waldegger S, Lampert A, Boehmer C, Waldegger P, Lang PA, Wissinger B, Friedrich B, Risler T, Moehle R, Lang UE, Zill P, Bondy B, Schaeffeler E, Asante-Poku S, Seyberth H, Schwab M, Lang F. Activating mutation of the renal epithelial chloride channel ClC-Kb predisposing to hypertension. Hypertension 2004;43:1175–81. 130. Bentzen J, Jorgensen T, Fenger M. The effect of six polymorphisms in the apolipoprotein B gene on parameters of lipid metabolism in a Danish population. Clin Genet 2002;61:126–34. 131. Hubacek JA, Pistulkova H, Skodova Z, Berg K, Poledne R. Association between apolipoprotein B promotor haplotypes and cholesterol status. Ann Clin Biochem 2001;38(pt 4):399–400. 132. Brown S, Ordovas JM, Campos H. Interaction between the APOC3 gene promoter polymorphisms, saturated fat intake and plasma lipoproteins. Atherosclerosis 2003;170:307–13. 133. Hein DW. Molecular genetics and function of NAT1 and NAT2: Role in aromatic amine metabolism and carcinogenesis. Mutat Res 2002;506–507:65–77. 134. Hein DW, Doll MA, Fretland AJ, Leff MA, Webb SJ, Xiao GH, Devanaboyina US, Nangju NA, Feng Y. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev 2000;9:29–42. 135. Ferre N, Camps J, Fernandez-Ballart J, Arija V, Murphy MM, Ceruelo S, Biarnes E, Vilella E, Tous M, Joven J. Regulation of serum paraoxonase activity by genetic, nutritional, and lifestyle factors in the general population. Clin Chem 2003;49:1491–7. 136. Chistyakov DA, Savost’anov KV, Zotova EV, Nosikov VV. Polymorphisms in the Mn-SOD and EC-SOD genes and their relationship to diabetic neuropathy in type 1 diabetes mellitus. BMC Med Genet 2001;2:4. 137. Van Landeghem GF, Tabatabaie P, Kucinskas V, Saha N, Beckman G. Ethnic variation in the mitochondrial targeting sequence polymorphism of MnSOD. Hum Hered 1999;49:190–3.
Page 1 and 2:
Contents International harmonizatio
Page 3 and 4:
Executive summary Harmonization of
Page 5 and 6:
Executive summary [11]. These are l
Page 7 and 8:
Executive summary and converted to
Page 9 and 10:
Executive summary very rapidly and
Page 11 and 12:
Executive summary References Concep
Page 13 and 14:
Introduction Janet C. King and Cutb
Page 15 and 16:
Introduction References 1. King JC,
Page 17 and 18:
Terminology and framework for nutri
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Nutrient risk assessment: Setting u
Page 29 and 30:
Setting upper levels for nutrient r
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Establishing nutrient intake values
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Methods for using nutrient intake v
Page 53 and 54:
Using nutrient intake values to ass
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Determining life-stage groups and e
Page 63 and 64: Life-stage groups and nutrient inta
Page 77 and 78: The role of diet- and host-related
Page 79 and 80: Diet- and host-related factors in n
Page 101 and 102: Human nutrition and genetic variati
Page 113: Human nutrition and genetic variati
Page 117 and 118: Application of nutrient intake valu
Page 123 and 124: Trade, development, and regulatory
Page 141 and 142: Beyond recommendations: Implementin
Page 143 and 144: Dietary guidelines and nutrient int
Page 153: International Dietary Harmonization
show all

Implementing food-based dietary guidelines for - United Nations ...

Create successful ePaper yourself

Delete template?

Save as template?